{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "T",
          "alt": "R",
          "position": "240"
        },
        "variant_string_id": "PARK2 T240R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Autosomal recessive juvenile parkinsonism (AR-JP) is characterized by selective dopaminergic neural cell death and the absence of the Lewy body. Mutations in PARK2 cause AR-JP, and the gene product, parkin, is involved in protein degradation as a ubiquitin-protein ligase.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the functional assay, linking PARK2 mutations to AR-JP through the loss of ubiquitin-protein ligase activity of parkin."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses ubiquitin-protein ligase activity assays to evaluate the functional impact of parkin mutations, which is directly relevant to the disease mechanism of protein degradation dysfunction.",
          "judgment": "Yes",
          "reasoning": "The general class of assay (ubiquitin-protein ligase activity) effectively models the disease pathogenesis defined in Step 1.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The study includes controls (wild-type parkin and other E2 enzymes) and replicates, and uses an in vitro ubiquitination assay to directly demonstrate parkin's E3 activity.",
          "judgment": "Yes",
          "reasoning": "Basic controls and replicates were used, and the assay's validity is supported by direct demonstration of E3 activity loss in mutant parkin.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The study shows that parkin T240R, a missense mutant from AR-JP patients, does not associate with UbcH7 and lacks ubiquitin-protein ligase activity.",
          "judgment": "Yes",
          "reasoning": "The variant's loss of function in ubiquitin-protein ligase activity directly correlates with the disease mechanism, supporting its pathogenic role.",
          "next_step_or_outcome": "Final evidence strength assessment"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The PARK2 T240R variant shows loss of ubiquitin-protein ligase activity, a key function related to AR-JP pathogenesis, supporting a moderate strength pathogenic evidence (PS3_moderate)."
    },
    {
      "variant_id": {
        "Gene": "PARK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "P",
          "position": "42"
        },
        "variant_string_id": "PARK2 R42P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "AR-JP is caused by mutations in PARK2, leading to loss of parkin's ubiquitin-protein ligase activity, which is crucial for protein degradation.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is well-defined, linking PARK2 mutations to AR-JP through impaired protein degradation."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Ubiquitin-protein ligase activity assays are used to assess the functional impact of parkin mutations, directly relevant to the disease mechanism.",
          "judgment": "Yes",
          "reasoning": "The assay class is appropriate for modeling the disease's molecular basis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "The study includes controls and replicates, and demonstrates that parkin R42P fails to co-immunoprecipitate ubiquitinated proteins despite binding UbcH7.",
          "judgment": "Yes",
          "reasoning": "The assay's validity is supported by controls and the specific functional deficit observed in the R42P variant.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Parkin R42P, with a mutation in the Ubl domain, fails to co-immunoprecipitate ubiquitinated proteins, indicating a loss of function in protein ubiquitination.",
          "judgment": "Yes",
          "reasoning": "The variant's functional impairment in protein ubiquitination supports its pathogenic role in AR-JP.",
          "next_step_or_outcome": "Final evidence strength assessment"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The PARK2 R42P variant exhibits a specific functional deficit in protein ubiquitination, supporting a supporting strength pathogenic evidence (PS3_supporting)."
    }
  ]
}